Gene sequencing company Illumina, Inc. said it filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom.
“Illumina is seeking all available remedies, including damages and injunctive relief,” said Illumina.
“The new suit accuses Premaitha’s IONA Test of infringing European Patent (UK) 1 524 321 B2 titled, ‘Non-invasive Detection of Fetal Genetic Traits’ which is exclusively licensed to Illumina from Sequenom, Inc.
“Illumina and its wholly subsidiary, Verinata Health, Inc., previously filed suits in the UK against Premaitha accusing its Iona test of infringing European Patent (UK) 0 994 963 B2, European Patent (UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent (UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1.
“Those suits remain pending.”
Premaitha Health CEO Stephen Little responded in a statement: “This latest claim uses old, publicly available information and we believe it is an attempt to abuse the legal process in the UK to obtain competitive advantage.
“That such large companies as Illumina and Sequenom should deem it necessary to compete in this way is disappointing but not unexpected, and we will robustly defend the company against these claims as well as bring their behaviour to the attention of the relevant competition authorities.”